Loading organizations...
Chroma Medicine, now operating as nChroma Bio, develops genetic medicines through targeted in vivo delivery of tailored genetic payloads. The company leverages advanced epigenetic editing technologies, aiming to harness nature's innate mechanisms for gene regulation. This approach is designed to produce potent and durable treatments, addressing the specific biological drivers of diseases with significant unmet medical needs. Their platform integrates best-in-class genetic cargoes with sophisticated delivery systems.
Chroma Medicine was founded in 2021, building on pioneering work in epigenetic editing. Its scientific founders include distinguished researchers such as Luke Gilbert, Keith Joung, David Liu, Angelo Lombardo, and Luigi Naldini. These experts shared an insight into the transformative potential of precisely controlling gene expression without altering the underlying DNA sequence, leading to the creation of their foundational platform. Chroma Medicine later merged with Nvelop Therapeutics in December 2024, forming nChroma Bio to enhance delivery capabilities.
nChroma Bio focuses on developing transformative, single-dose genomic medicines for patients confronting serious illnesses. The company's vision centers on applying its integrated genetic cargo and targeted delivery platform to unlock the full therapeutic potential of genetic medicine. They seek to modulate gene expression with precision to provide lasting benefits, thereby overcoming limitations of existing therapies and ultimately improving long-term patient outcomes.
Chroma Medicine has raised $265.0M across 2 funding rounds.
Chroma Medicine has raised $265.0M in total across 2 funding rounds.
Chroma Medicine has raised $265.0M in total across 2 funding rounds.
Chroma Medicine's investors include GV, ARCH Venture Partners, David Schenkein, Lux Capital, Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, DCVC Bio, Janus Henderson Investors, Mubadala Capital, Newpath Partners.
Chroma Medicine is a biotechnology company developing single-dose epigenetic editing therapeutics that precisely regulate gene expression without altering the underlying DNA sequence. Their platform harnesses the cell’s natural epigenome to durably silence, activate, or multiplex genes, aiming to treat a broad range of diseases—including those with complex genetic pathways—while avoiding risks associated with traditional gene editing methods that cut DNA[2][3][4]. The company serves patients with genetic and complex diseases by providing potentially safer, more precise, and durable genomic medicines, demonstrating strong growth momentum with a $135 million Series B funding round in 2023 to expand their pipeline and technology platform[2].
Chroma Medicine was founded in late 2021 by scientific leaders in epigenetics and genomic medicine, launching with a significant $125 million Series A financing to pioneer epigenetic editing as a new therapeutic modality[5]. The idea emerged from advances in understanding epigenetics as a natural mechanism for gene regulation, offering a novel approach to treat diseases previously inaccessible to conventional gene editing. Early traction includes exclusive licensing agreements and data demonstrating durable multiplex editing capabilities, positioning Chroma as a leader in this emerging field[3][4].
Chroma Medicine rides the wave of genomic medicine innovation, particularly the shift from DNA-cutting gene editing to epigenetic modulation, which offers a safer and more versatile approach to gene therapy. The timing is critical as the field seeks alternatives to CRISPR’s limitations, with growing demand for therapies that can target non-coding regions and complex gene networks. Market forces favor companies that can deliver precise, durable, and multiplex gene regulation, positioning Chroma to influence the future of genetic medicine and expand the therapeutic landscape for rare and complex diseases[2][5].
Looking ahead, Chroma Medicine is poised to advance its epigenetic editing platform into clinical development, potentially transforming treatment paradigms for genetic and multifactorial diseases. Trends such as increasing understanding of the epigenome, regulatory acceptance of novel gene therapies, and demand for safer, one-time treatments will shape their trajectory. Their influence may grow as they demonstrate clinical success and expand applications, potentially setting new standards for genomic medicine beyond DNA editing. This evolution ties back to their core mission: harnessing nature’s own gene regulation mechanisms to unlock new therapeutic possibilities[2][5].
Chroma Medicine has raised $265.0M across 2 funding rounds. Most recently, it raised $140.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $140.0M Series B | GV | ARCH Venture Partners, David Schenkein, Lux Capital, Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, DCVC Bio, Janus Henderson Investors, Mubadala Capital, Newpath Partners, Omega Funds, Osage University Partners, Sixth Street Growth, Sofinnova Partners, T. Rowe Price Associates, Wellington Management |
| Nov 17, 2021 | $125.0M Series A | Bihua Chen | Kevin Bitterman, Casdin Capital, Janus Henderson Investors, Thomas Cahill, Omega Funds, Paola Pozzi, T. Rowe Price Associates, Wellington Management |